FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2796102942> ?p ?o ?g. }

• W2796102942 endingPage "2594" @default.
• W2796102942 startingPage "2588" @default.
• W2796102942 abstract "This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent). Of 43 patients enrolled, 74% were refractory to bortezomib and 23% had high-risk cytogenetics. No dose-limiting toxicities were observed. The recommended phase 2 dose was ibrutinib 840 mg and carfilzomib 36 mg/m2 with dexamethasone. The most common ≥ grade 3 (>10%) treatment-emergent adverse events were hypertension, anemia, pneumonia, fatigue, diarrhea, and thrombocytopenia. Overall response rate was 67% (very good partial response, 21%; stringent complete response, 2%), with an additional 9% minimal response. Median progression-free survival was 7.2 months and was not inferior in refractory nor high-risk patients. Median overall survival was not reached. Ibrutinib plus carfilzomib demonstrated encouraging responses with a manageable safety profile in this advanced population." @default.
• W2796102942 created "2018-04-13" @default.
• W2796102942 creator A5006108161 @default.
• W2796102942 creator A5013834732 @default.
• W2796102942 creator A5015464068 @default.
• W2796102942 creator A5028564534 @default.
• W2796102942 creator A5033267787 @default.
• W2796102942 creator A5033550793 @default.
• W2796102942 creator A5037850152 @default.
• W2796102942 creator A5039067043 @default.
• W2796102942 creator A5041161932 @default.
• W2796102942 creator A5049900530 @default.
• W2796102942 creator A5050097218 @default.
• W2796102942 creator A5055012214 @default.
• W2796102942 creator A5058193715 @default.
• W2796102942 creator A5062827052 @default.
• W2796102942 creator A5072484302 @default.
• W2796102942 creator A5077846750 @default.
• W2796102942 creator A5083639923 @default.
• W2796102942 creator A5086403929 @default.
• W2796102942 creator A5088179815 @default.
• W2796102942 date "2018-04-04" @default.
• W2796102942 modified "2023-09-23" @default.
• W2796102942 title "Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma" @default.
• W2796102942 cites W1956158886 @default.
• W2796102942 cites W2003734726 @default.
• W2796102942 cites W2033880166 @default.
• W2796102942 cites W2082863510 @default.
• W2796102942 cites W2089311432 @default.
• W2796102942 cites W2110474703 @default.
• W2796102942 cites W2140579395 @default.
• W2796102942 cites W2193716145 @default.
• W2796102942 cites W2205355516 @default.
• W2796102942 cites W2289073710 @default.
• W2796102942 cites W2336872381 @default.
• W2796102942 cites W2340733378 @default.
• W2796102942 cites W2767324513 @default.
• W2796102942 doi "https://doi.org/10.1080/10428194.2018.1443337" @default.
• W2796102942 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29616843" @default.
• W2796102942 hasPublicationYear "2018" @default.
• W2796102942 type Work @default.
• W2796102942 sameAs 2796102942 @default.
• W2796102942 citedByCount "22" @default.
• W2796102942 countsByYear W27961029422018 @default.
• W2796102942 countsByYear W27961029422019 @default.
• W2796102942 countsByYear W27961029422020 @default.
• W2796102942 countsByYear W27961029422021 @default.
• W2796102942 countsByYear W27961029422022 @default.
• W2796102942 crossrefType "journal-article" @default.
• W2796102942 hasAuthorship W2796102942A5006108161 @default.
• W2796102942 hasAuthorship W2796102942A5013834732 @default.
• W2796102942 hasAuthorship W2796102942A5015464068 @default.
• W2796102942 hasAuthorship W2796102942A5028564534 @default.
• W2796102942 hasAuthorship W2796102942A5033267787 @default.
• W2796102942 hasAuthorship W2796102942A5033550793 @default.
• W2796102942 hasAuthorship W2796102942A5037850152 @default.
• W2796102942 hasAuthorship W2796102942A5039067043 @default.
• W2796102942 hasAuthorship W2796102942A5041161932 @default.
• W2796102942 hasAuthorship W2796102942A5049900530 @default.
• W2796102942 hasAuthorship W2796102942A5050097218 @default.
• W2796102942 hasAuthorship W2796102942A5055012214 @default.
• W2796102942 hasAuthorship W2796102942A5058193715 @default.
• W2796102942 hasAuthorship W2796102942A5062827052 @default.
• W2796102942 hasAuthorship W2796102942A5072484302 @default.
• W2796102942 hasAuthorship W2796102942A5077846750 @default.
• W2796102942 hasAuthorship W2796102942A5083639923 @default.
• W2796102942 hasAuthorship W2796102942A5086403929 @default.
• W2796102942 hasAuthorship W2796102942A5088179815 @default.
• W2796102942 hasBestOaLocation W27961029421 @default.
• W2796102942 hasConcept C121332964 @default.
• W2796102942 hasConcept C126322002 @default.
• W2796102942 hasConcept C142424586 @default.
• W2796102942 hasConcept C143998085 @default.
• W2796102942 hasConcept C197934379 @default.
• W2796102942 hasConcept C2776063141 @default.
• W2796102942 hasConcept C2776364478 @default.
• W2796102942 hasConcept C2776694085 @default.
• W2796102942 hasConcept C2777478702 @default.
• W2796102942 hasConcept C2777938653 @default.
• W2796102942 hasConcept C2778461978 @default.
• W2796102942 hasConcept C2778496288 @default.
• W2796102942 hasConcept C2778524551 @default.
• W2796102942 hasConcept C2779609412 @default.
• W2796102942 hasConcept C2779878957 @default.
• W2796102942 hasConcept C2780108899 @default.
• W2796102942 hasConcept C2780775027 @default.
• W2796102942 hasConcept C2908647359 @default.
• W2796102942 hasConcept C71924100 @default.
• W2796102942 hasConcept C87355193 @default.
• W2796102942 hasConcept C99454951 @default.
• W2796102942 hasConceptScore W2796102942C121332964 @default.
• W2796102942 hasConceptScore W2796102942C126322002 @default.
• W2796102942 hasConceptScore W2796102942C142424586 @default.
• W2796102942 hasConceptScore W2796102942C143998085 @default.
• W2796102942 hasConceptScore W2796102942C197934379 @default.
• W2796102942 hasConceptScore W2796102942C2776063141 @default.
• W2796102942 hasConceptScore W2796102942C2776364478 @default.
• W2796102942 hasConceptScore W2796102942C2776694085 @default.

• next